

Stephen Forman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3737827/stephen-forman-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

714
papers

12,181
citations

54
h-index

102
g-index

801
ext. papers

14,898
ext. citations

4.4
avg. IF

5.99
L-index

#	Paper	IF	Citations
714	CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.. <i>Leukemia</i> , 2022 ,	10.7	2
713	Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity.. <i>Blood Advances</i> , 2022 ,	7.8	1
712	Large-scale manufacturing and characterization of CMV-CD19CAR T cells. 2022 , 10,		1
711	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
710	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	0
709	Single-cell analysis by mass cytometry reveals CD19 CAR T cell spatiotemporal plasticity in patients.. <i>Onc Immunology</i> , 2022 , 11, 2040772	7.2	0
708	Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102372	2.2	0
707	3D-organoid culture supports differentiation of human CAR iPSCs into highly functional CAR T cells.. <i>Cell Stem Cell</i> , 2022 ,	18	2
706	Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	1
705	Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine.. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022 , 25, 344-359	6.4	1
704	Loss of SIRT1 inhibits hematopoietic stem cell aging and age-dependent mixed phenotype acute leukemia.. <i>Communications Biology</i> , 2022 , 5, 396	6.7	0
703	Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.. <i>Neoplasia</i> , 2022 , 30, 100801	6.4	1
702	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021 , 138, 133-133	2.2	3
701	Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade. <i>Blood</i> , 2021 , 138, 234-234	2.2	
700	Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor. <i>Blood</i> , 2021 , 138, 1715-1715	2.2	
699	Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL). <i>Blood</i> , 2021 , 138, 2836-2836	2.2	0
698	Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. <i>Blood</i> , 2021 , 138, 3037-3037	2.2	

697	Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation - a BMTSS Report. <i>Blood</i> , 2021 , 138, 3923-3923	2.2	
696	Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation (BMT) Performed over Three Decades - a BMT Survivor Study (BMTSS) Report. <i>Blood</i> , 2021 , 138, 484-484 ^{2,2}		
695	CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 2783-2783	2.2	
694	Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity. <i>Blood</i> , 2021 , 138, 2796-2796	2.2	
693	A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021 , 138, 334-334	2.2	
692	Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association. <i>Blood</i> , 2021 , 138, 3887-3887	2.2	
691	Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq. <i>Blood</i> , 2021 , 138, 1808-1808	2.2	
690	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021 , 138, 3955-3955	2.2	
689	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant. <i>Blood</i> , 2021 , 138, 2887-2887	2.2	
688	Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. <i>Blood</i> , 2021 , 138, 2502-2502	2.2	1
687	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy. <i>Transplantation and Cellular Therapy</i> , 2021 ,		2
686	The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type. <i>Blood</i> , 2021 , 138, 1776-1776	2.2	
685	Conditioning Intensity and Probability of Live Birth after Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2021 , 138, 2905-2905	2.2	
684	Social Vulnerability Is a Clinically Important Predictor of Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021 , 138, 842-842	2.2	0
683	CTIM-29. CLINICAL EVALUATION OF CHLOROTOXIN-DIRECTED CAR T CELLS FOR PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021 , 23, vi57-vi57		1
682	Single-Cell Analysis By Mass Cytometry Reveals CD19 CAR T Cell Spatiotemporal Plasticity in Patients. <i>Blood</i> , 2021 , 138, 2794-2794	2.2	
681	Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL). <i>Cancer Treatment and Research</i> , 2021 , 181, 179-196	3.5	0
680	Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2

679	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2021 ,	6.4	2
678	Donor derived leukemia in allogeneic transplantation. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2823-2830	1.9	0
677	Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021 , 39, 902-910	2.2	1
676	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 255.e1-255.e9 ¹		
675	Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021 , 106, 851-858	3.8	1
674	Targeted InVivo Delivery of NF-B Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. <i>Molecular Therapy</i> , 2021 , 29, 1214-1225	11.7	1
673	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351). <i>American Journal of Hematology</i> , 2021 , 96, E196-E200	7.1	4
672	IFN̄s Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. <i>Cancer Discovery</i> , 2021 , 11, 2248-2265	24.4	21
671	Efficacy of blinatumomab for MRD relapse in ALL post allogeneic HCT. <i>Leukemia Research</i> , 2021 , 104, 1065-1079	5.7	2
670	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2464-2470	4.4	0
669	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3328-3339	2.2	14
668	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. <i>Leukemia</i> , 2021 , 35, 189-200	10.7	25
667	Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. <i>Cancer</i> , 2021 , 127, 794-800	6.4	1
666	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. <i>Cancer Discovery</i> , 2021 , 11, 1192-1211	24.4	21
665	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021 , 9, 75-88	12.5	10
664	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. <i>Blood</i> , 2021 , 137, 471-484	2.2	28
663	Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents. <i>American Journal of Hematology</i> , 2021 , 96, E140-E143	7.1	1
662	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 125	7	0

661	Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. <i>Molecular Therapy</i> , 2021 , 29, 2335-2349	11.7	14
660	Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 938.e1-938.e6	20	
659	Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. <i>Blood Advances</i> , 2021 , 5, 4102-4111	7.8	1
658	Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation Survivors. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2073-2076.e5	4.3	
657	Treatment of allosensitized patients receiving allogeneic transplantation. <i>Blood Advances</i> , 2021 , 5, 4031-4043	3	
656	Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021 , 114, 544-553	2.3	0
655	Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. <i>Frontiers in Immunology</i> , 2021 , 12, 700045	8.4	0
654	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. <i>Blood Advances</i> , 2021 , 5, 4059-4063	7.8	10
653	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 837.e1-837.e10		
652	Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma.. <i>Cancer</i> , 2021 ,	6.4	1
651	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2021 , 1-7	1.9	
650	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.. <i>British Journal of Haematology</i> , 2021 ,	4.5	0
649	State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid Leukemia. <i>Cancer Research</i> , 2020 , 80, 3157-3169	10.1	8
648	Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. <i>Cancer</i> , 2020 , 126, 3322-3329	6.4	2
647	Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2139-2145	7.4	6
646	Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e667-e672	2	2
645	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1425-1432	4.7	2
644	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1697-1703	4.7	3

643	Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch. <i>Transplantation</i> , 2020 , 104, 1070-1080	1.8	3
642	Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	68
641	The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2020-2023	1.9	11
640	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 962-972	10.3	5
639	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 1193	7.1	13
638	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1084-1090	4.7	11
637	Self-endorsed cognitive problems versus objectively assessed cognitive impairment in blood or bone marrow transplantation recipients: A longitudinal study. <i>Cancer</i> , 2020 , 126, 2174-2182	6.4	2
636	Clinical and Genetic Risk Prediction of Cognitive Impairment After Blood or Marrow Transplantation for Hematologic Malignancy. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1312-1321	2.2	5
635	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020 , 26, 1034-1044	12.9	25
634	Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1669-1677	1.9	4
633	Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases. <i>Blood</i> , 2020 , 136, 5-6	2.2	
632	Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. <i>Blood</i> , 2020 , 136, 40-41	2.2	
631	Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis. <i>Blood</i> , 2020 , 136, 21-22	2.2	
630	Severe/Life-Threatening/Fatal Chronic Health Conditions (CHCs) after Allogeneic Blood or Marrow Transplantation (BMT) in Childhood - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2020 , 136, 12-13	2.2	
629	Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program. <i>Blood</i> , 2020 , 136, 10-10	2.2	
628	Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2020 , 136, 10-11	2.2	
627	Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors. <i>Blood</i> , 2020 , 136, 17-18	2.2	
626	Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020 , 136, 11-18	2.2	1

625	Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization. <i>Blood</i> , 2020 , 136, 16-17	2.2	
624	Haploidentical mixed chimerism cures autoimmunity in established type 1 diabetic mice. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6457-6476	15.9	2
623	Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 19-20	2.2	7
622	A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network	2.2	9
621	Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). <i>Blood</i> , 2020 , 136, 37-38	2.2	1
620	Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial. <i>Blood</i> , 2020 , 136, 49-50	2.2	2
619	Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1386-1393	4.7	2
618	Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1153-1161	9.7	6
617	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 877-883	4.4	6
616	Integrin β signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells. <i>Oncogene</i> , 2020 , 39, 2156-2169	9.2	10
615	Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. <i>JAMA Oncology</i> , 2020 , 6, 1947-1951	13.4	15
614	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia 2020 , 8,		2
613	Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2872-2882	2.2	2
612	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e322-e327	4.7	19
611	Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy. <i>Blood Advances</i> , 2020 , 4, 4798-4801	7.8	5
610	Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
609	Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3532-3533	1.9	1
608	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020 , 55, 473-475	4.4	9

607	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 292-299	4.7	5
606	Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 409-418	4.4	3
605	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2020 , 61, 309-317	1.9	8
604	Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1662-1664	4.4	3
603	Myeloid cell-targeted miR-146a mimic inhibits NF- κ B-driven inflammation and leukemia progression in vivo. <i>Blood</i> , 2020 , 135, 167-180	2.2	40
602	How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. <i>Blood</i> , 2020 , 135, 804-813	2.2	23
601	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1934-1941	1.9	3
600	Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019 , 187, e45-e48	4.5	26
599	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2517-2521	4.7	9
598	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. <i>Cell Stem Cell</i> , 2019 , 25, 542-557.e9	18	23
597	Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 1025-1033	4	19
596	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	37
595	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e400-e405	2	3
594	Acute Lymphoblastic Leukemia in the Older Adult. <i>Journal of Oncology Practice</i> , 2019 , 15, 67-75	3.1	23
593	IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. <i>Cancer Immunology Research</i> , 2019 , 7, 759-772	12.5	109
592	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 978-986	5.6	16
591	Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. <i>British Journal of Haematology</i> , 2019 , 186, 367-370	4.5	3
590	In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	7

589	Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e183-e185	4.7	4
588	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. <i>Leukemia</i> , 2019 , 33, 266-270	10.7	8
587	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2383-2387	4.7	10
586	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. <i>Cancer</i> , 2019 , 125, 4033-4042	6.4	1
585	Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2261-2266	4.7	2
584	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2160-2166	4.7	15
583	The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. <i>Leukemia Research</i> , 2019 , 84, 106196	2.7	4
582	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019 , 25, 5143-5155	12.9	6
581	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019 , 94, E253-E255	7.1	26
580	Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. <i>Leukemia Research</i> , 2019 , 87, 106230	2.7	6
579	PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 239-239	2.2	21
578	Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 759-759	2.2	14
577	Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas. <i>Blood</i> , 2019 , 134, 4023-4023	2.2	4
576	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. <i>Blood</i> , 2019 , 134, 4075-4075	2.2	6
575	First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results. <i>Blood</i> , 2019 , 134, 4394-4394	2.2	1
574	Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning. <i>Blood</i> , 2019 , 134, 669-669	2.2	4
573	Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. <i>Blood</i> , 2019 , 134, 4518-4518	2.2	1
572	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. <i>Blood</i> , 2019 , 134, 4525-4525	2.2	1

571	YIA19-005: Immunotherapy for Prostate Cancer Combining CAR-Engineered T Cells with Targeted Immune Checkpoint Inhibition. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, YIA19-005	7.3	
570	Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant Recipients: ESPRIT). <i>Blood</i> , 2019 , 134, 4477-4477	2.2	0
569	Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R. <i>Blood</i> , 2019 , 134, 3871-3871	2.2	
568	Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2019 , 134, 707-707	2.2	0
567	Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS). <i>Blood</i> , 2019 , 134, 699-699	2.2	
566	Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. <i>Blood</i> , 2019 , 134, 5729-5729	2.2	1
565	Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors. <i>Blood</i> , 2019 , 134, 2011-2011	2.2	
564	Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 287-292	4.7	2
563	Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 265-269	4.7	44
562	The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. <i>Journal of Cellular Physiology</i> , 2019 , 234, 14040-14049	7	25
561	Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e41-e45	4.7	11
560	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2018 , 32, 1567-1574	10.7	31
559	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. <i>Nature Medicine</i> , 2018 , 24, 450-462	50.5	69
558	Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. <i>Blood</i> , 2018 , 131, 2720-2729	2.2	6
557	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. <i>Molecular Therapy</i> , 2018 , 26, 695-707	11.7	17
556	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 700-707	4.7	9
555	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>Haematologica</i> , 2018 , 103, e404-e407	6.6	131
554	Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Breast Cancer Metastasis to the Brain. <i>Clinical Cancer Research</i> , 2018 , 24, 95-105	12.9	139

553	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. <i>Clinical Cancer Research</i> , 2018 , 24, 106-119	12.9	88
552	Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. <i>Molecular Therapy</i> , 2018 , 26, 280-288	11.7	53
551	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>Oncolmmunology</i> , 2018 , 7, e1380764	7.2	74
550	Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. <i>Leukemia</i> , 2018 , 32, 2706-2709	10.7	1
549	Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. <i>JAMA Oncology</i> , 2018 , 4, e182453	13.4	15
548	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 87	22.4	8
547	PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with Zr-Oxine. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1531-1537	8.9	70
546	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1828-1835	4.7	9
545	Regulation of miR-34b/c-targeted gene expression program by SUMOylation. <i>Nucleic Acids Research</i> , 2018 , 46, 7108-7123	20.1	11
544	Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. <i>Haematologica</i> , 2018 , 103, 1662-1668	6.6	26
543	Self-Endorsed Cognitive Problems Vs. Objectively-Assessed Cognitive Impairment in Blood or Marrow Transplantation (BMT) Recipients in a Longitudinal Study. <i>Blood</i> , 2018 , 132, 619-619	2.2	2
542	Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 1636-1636	2.2	5
541	Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2018 , 132, 1552-1552	2.2	3
540	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 2177-2177	2.2	2
539	The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma. <i>Blood</i> , 2018 , 132, 965-965	2.2	2
538	CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL. <i>Blood</i> , 2018 , 132, 610-610	2.2	5
537	Adult Patients with ALL Treated with CD62L+ T Naive/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile. <i>Blood</i> , 2018 , 132, 4016-4016	2.2	7
536	Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. <i>Blood</i> , 2018 , 132, 3416-3416	2.2	0

535	MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis. <i>Blood</i> , 2018 , 132, 1752-1752 ^{2,2}		
534	Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. <i>Blood</i> , 2018 , 132, 1411-1411		
533	Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 1549-1549	2.2	
532	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018 , 132, 3386-3386	2.2	
531	Venous Thromboembolism in Blood or Marrow Transplant (BMT) Survivors: A Report from BMT Survivor Study (BMTSS). <i>Blood</i> , 2018 , 132, 823-823	2.2	
530	Targeted Delivery of CpG-Mir-146a Mimic Oligonucleotides As a Therapeutic Strategy to Reduce NF- κ -Mediated Pathogenic Inflammation and Myeloid Leukemia Progression. <i>Blood</i> , 2018 , 132, 3501-3501 ²		
529	Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study. <i>Blood</i> , 2018 , 132, 2007-2007	2.2	
528	Burden of Morbidity Borne By Survivors of Multiple Myeloma (MM) Treated with Autologous Blood or Marrow Transplant (BMT) [Results of the BMT Survivor Study (BMTSS)]. <i>Blood</i> , 2018 , 132, 2127-2127	2.2	
527	DNA Repair Genes May Influence Cognitive Outcomes in Adult Patients with Hematologic Malignancies (HM) Treated with Blood or Marrow Transplantation (BMT). <i>Blood</i> , 2018 , 132, 3411-3411	2.2	
526	Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018 , 132, 620-620	2.2	
525	Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation. <i>Blood</i> , 2018 , 132, 2181-2181	2.2	
524	CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies. <i>Blood</i> , 2018 , 132, 776-776	2.2	
523	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 514-520	4.7	27
522	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 726-733	4.7	45
521	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 486-493	4.7	2
520	Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. <i>Cancer</i> , 2018 , 124, 850-857	6.4	9
519	Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 463-475	2.2	38
518	Effective Targeting of TAG72 Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 2268	8.4	44

517	Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. <i>Blood Advances</i> , 2018 , 2, 1756-1764	7.8	23
516	Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	196
515	Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 691-696	4.7	30
514	Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 700-705	4.7	19
513	Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 618-624	4.7	54
512	Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 922-929	4.7	7
511	Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1264-1268	4.7	1
510	Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 858-865	7.1	100
509	Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. <i>Cytotherapy</i> , 2017 , 19, 861-866	4.8	12
508	Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. <i>Leukemia Research</i> , 2017 , 59, 124-135	2.7	18
507	HIV infection and transplantation 2017 , 290-296		
506	Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy 2017 , 5, 26		40
505	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017 , 176, 759-769	4.5	26
504	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017 , 179, 781-789	4.5	36
503	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of mutational status. <i>Haematologica</i> , 2017 , 102, 2030-2038	6.6	17
502	Extrafollicular CD4 T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017 , 8, 978	17.4	35
501	Are Disagreements in Caregiver and Patient Assessment of Patient Health Associated with Increased Caregiver Burden in Caregivers of Older Adults with Cancer?. <i>Oncologist</i> , 2017 , 22, 1383-1391	5.7	17
500	How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation. <i>Blood</i> , 2017 , 130, 1976-1984	2.2	11

499	CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. <i>Cancer Research</i> , 2017 , 77, 5118-5128	10.1	17
498	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1861-1869	4.7	18
497	Stabilization of the c-Myc Protein by CAMKII β Promotes T Cell Lymphoma. <i>Cancer Cell</i> , 2017 , 32, 115-128.	7.3	38
496	Philadelphia chromosome as a recurrent event among therapy-related acute leukemia. <i>American Journal of Hematology</i> , 2017 , 92, E18-E19	7.1	7
495	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 24-31	2.2	105
494	Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 478-488	12.9	110
493	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2017 ,	10.7	6
492	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017 , 130, 738-738	2.2	5
491	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 268-276	4.7	24
490	Comparison of naive and central memory derived CD8 effector cell engraftment fitness and function following adoptive transfer. <i>Oncotmunology</i> , 2016 , 5, e1072671	7.2	14
489	US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. <i>Blood Advances</i> , 2016 , 1, 250-259	7.8	91
488	Respiratory Viruses After Hematopoietic Cell Transplantation 2016 , 1112-1125		
487	Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1900-1903	4.7	37
486	Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia 2016 , 545-556		
485	Immune Reconstitution Following Hematopoietic Cell Transplantation 2016 , 160-169		3
484	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancer Cell</i> , 2016 , 30, 764-778	24.3	84
483	Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study. <i>JAMA Oncology</i> , 2016 , 2, 1277-1286	13.4	63
482	Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 519-522	2	4

481	Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. <i>Lancet Haematology, the</i> , 2016 , 3, e87-98	14.6	56
480	Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 575-8	4.7	25
479	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 679-679	2.2	3
478	Inhibition of MDR1 Overcomes Brentuximab Vedotin Resistance in Hodgkin Lymphoma Cell Line Model and Is Synergistic with Brentuximab Vedotin in Mouse Xenograft Model. <i>Blood</i> , 2016 , 128, 752-752 ²	2.2	5
477	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor Redirected-T Cells Against Multiple Myeloma. <i>Blood</i> , 2016 , 128, 812-812	2.2	4
476	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 986-986	2.2	1
475	New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. <i>Blood</i> , 2016 , 128, 2161-2161	2.2	
474	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. <i>Blood</i> , 2016 , 128, 4651-4651	2.2	
473	L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. <i>PLoS ONE</i> , 2016 , 11, e0146885	3.7	28
472	Cryopreservation of Hematopoietic Cells 2016 , 469-481		
471	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, e1025-e1034	3.1	54
470	Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 2561-9	59.2	897
469	Identification of a CD133-CD55- population functions as a fetal common skeletal progenitor. <i>Scientific Reports</i> , 2016 , 6, 38632	4.9	3
468	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia 2016 , 4, 90		14
467	Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1212-1217	4.7	9
466	CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. <i>Immunity</i> , 2016 , 44, 913-923	32.3	94
465	Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 1687-700	2.2	55
464	Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. <i>Blood</i> , 2016 , 127, 2249-60	2.2	54

463	Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. <i>Blood</i> , 2016 , 127, 2980-90	2.2	191
462	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. <i>Blood</i> , 2016 , 128, 1050-8	2.2	61
461	A History of Allogeneic and Autologous Hematopoietic Cell Transplantation 2016 , 1-11		
460	Histocompatibility 2016 , 112-127		1
459	Biology of the Human Graft-versus-Tumor Response and How to Exploit It 2016 , 166-181		1
458	Uses and Growth of Hematopoietic Cell Transplantation 2016 , 8-17		3
457	Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Pluripotent Stem Cells 2016 , 16-26		1
456	Hematopoietic Stem Cells, Regenerative Medicine, and Leukemogenesis 2016 , 25-57		2
455	Marrow Microenvironment and Biology of Mobilization of Stem Cells 2016 , 50-67		
454	Expansion of Human Hematopoietic Stem Cells 2016 , 62-70		
453	Hematopoietic Cell Therapy for Human Immunodeficiency Virus Infection 2016 , 781-793		1
452	Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation 2016 , 69-79		
451	Hematopoietic Cell Transplantation for Immunodeficiency Diseases 2016 , 866-889		
450	Genetic Manipulation of Hematopoietic Stem Cells 2016 , 78-99		
449	Overview of Hematopoietic Cell Transplantation Immunology 2016 , 96-114		
448	Oral Complications of Hematopoietic Cell Transplantation 2016 , 1242-1258		1
447	Growth and Development After Hematopoietic Cell Transplantation 2016 , 1257-1268		
446	Delayed Non-malignant Complications After Hematopoietic Cell Transplantation 2016 , 1266-1276		

445	Subsequent Malignant Neoplasms After Hematopoietic Cell Transplantation 2016 , 1275-1289	1
444	Neurologic Complications of Hematopoietic Cell Transplantation 2016 , 1287-1298	1
443	Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients 2016 , 1297-1306	
442	Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation 2016 , 126-138	
441	Mechanisms of Tolerance 2016 , 136-149	1
440	The Pathophysiology of Graft-versus-Host Disease 2016 , 146-155	4
439	Immune Regulation in Hematopoietic Cell Transplantation 2016 , 153-162	
438	Dendritic Cells in Hematopoietic Cell Transplantation 2016 , 178-194	
437	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases 2016 , 191-214	1
436	Pharmacologic Basis for High-dose Chemotherapy 2016 , 211-224	0
435	High-dose Preparatory Regimens 2016 , 223-234	0
434	Reduced-intensity Allogeneic Transplantation Regimens 2016 , 232-246	
433	Radiotherapeutic Principles of Hematopoietic Cell Transplantation 2016 , 244-261	
432	Radioimmunotherapy and Hematopoietic Cell Transplantation 2016 , 258-275	
431	Documentation of Engraftment and Characterization of Chimerism After Hematopoietic Cell Transplantation 2016 , 272-282	1
430	The Detection and Significance of Minimal Residual Disease 2016 , 281-296	
429	Pathology of Hematopoietic Cell Transplantation 2016 , 292-332	3
428	Biostatistical Methods in Hematopoietic Cell Transplantation 2016 , 329-341	

- 427 Outcomes Research in Hematopoietic Cell Transplantation **2016**, 341-350
- 426 The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation **2016**, 349-365
- 425 Nursing Role in Hematopoietic Cell Transplantation **2016**, 362-374 1
- 424 Ethical Issues in Hematopoietic Cell Transplantation **2016**, 374-385
- 423 Psychosocial Issues in Hematopoietic Cell Transplantation **2016**, 384-393
- 422 Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients **2016**, 392-401 1
- 421 Sexuality Following Hematopoietic Cell Transplantation **2016**, 399-408
- 420 Hematopoietic Cell Transplantation **2016**, 407-414
- 419 Hematopoietic Cell Procurement, Processing, and Transplantation **2016**, 414-424 1
- 418 Bone Marrow and Peripheral Blood Cell Donors and Donor Registries **2016**, 423-432 1
- 417 The Role of the Transplant Program in a Nuclear Accident or Terrorism **2016**, 431-437
- 416 Cord Blood Hematopoietic Cell Transplantation **2016**, 437-455 5
- 415 Mobilization of Peripheral Blood Hematopoietic Cells for Autologous HCT **2016**, 452-462 1
- 414 Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation **2016**, 460-471 1
- 413 Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation **2016**, 480-491
- 412 Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors **2016**, 489-508
- 411 Hematopoietic Cell Transplantation from Unrelated Donors **2016**, 505-520
- 410 Hematopoietic Cell Transplantation for Aplastic Anemia **2016**, 517-540 1

409 Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria **2016**, 537-546

408 Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia **2016**, 554-565

407 Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia **2016**, 563-577

406 Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia **2016**, 576-590

405 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children **2016**, 600-617

404 Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms **2016**, 613-627

403 Hematopoietic Cell Transplantation for Multiple Myeloma **2016**, 625-639

402 Hematopoietic Cell Transplantation for Hodgkin Disease **2016**, 675-695

401 Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma (B Cell) **2016**, 692-705

400 Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma (T Cell) **2016**, 703-716

399 Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia **2016**, 714-726

398 Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis **2016**, 724-741 1

397 Autologous Hematopoietic Cell Transplantation for Breast Cancer and Germ-cell Tumors **2016**, 739-750

396 Hematopoietic Cell Transplantation for Renal Cell Carcinoma and Other Solid Tumors **2016**, 748-761

395 Hematopoietic Cell Transplantation for Neuroblastoma **2016**, 760-770

394 Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors **2016**, 768-784

393 Hematopoietic Cell Transplantation for Autoimmune Diseases **2016**, 792-806

392 Adoptive T-cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation **2016**, 816-827

- 391 Relapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation **2016**, 836-844
- 390 Hematopoietic Cell Transplantation for Thalassemia **2016**, 842-854 1
- 389 Hematopoietic Cell Transplantation for Sickle Cell Disease **2016**, 853-868
- 388 Hematopoietic Cell Transplantation for Storage Diseases **2016**, 885-912
- 387 Hematopoietic Cell Transplantation for Macrophage, Granulocyte and Osteoclast Disorders **2016**, 910-925
- 386 Hematopoietic Cell Transplantation for Fanconi Anemia **2016**, 923-946 1
- 385 Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation **2016**, 955-962 1
- 384 Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation **2016**, 961-979 1
- 383 Vascular Access and Complications **2016**, 976-991
- 382 Pharmacologic Prevention of Acute Graft-versus-Host Disease **2016**, 990-1006 3
- 381 T-cell Depletion to Prevent Graft-versus-Host Disease **2016**, 1004-1014
- 380 Manifestations and Treatment of Acute Graft-versus-Host Disease **2016**, 1012-1025 5
- 379 Chronic Graft-versus-Host Disease [Clinical Manifestations and Therapy] **2016**, 1020-1039 1
- 378 Fungal Infections After Hematopoietic Cell Transplantation **2016**, 1057-1071 1
- 377 Cytomegalovirus Infection **2016**, 1069-1079 2
- 376 Herpes Simplex Virus Infections **2016**, 1078-1086
- 375 Varicella Zoster Virus Infections **2016**, 1085-1110 1
- 374 EpsteinBarr Virus Infection **2016**, 1105-1113

373	HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation 2016 , 1122-1131		
372	Human Adenovirus, Polyomavirus, and Parvovirus Infections in Patients Undergoing Hematopoietic Stem Cell Transplantation 2016 , 1129-1143		3
371	Gastrointestinal and Hepatic Complications 2016 , 1140-1160		4
370	Lung Injury Following Hematopoietic Cell Transplantation 2016 , 1156-1172		1
369	Kidney and Bladder Complications of Hematopoietic Cell Transplantation 2016 , 1170-1184		
368	Endocrine Complications Following Hematopoietic Cell Transplantation 2016 , 1181-1207		1
367	Common Potential Drug Interactions Following Hematopoietic Cell Transplantation 2016 , 1206-1217		1
366	Nutrition Support of the Hematopoietic Cell Transplant Recipient 2016 , 1216-1226		1
365	Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort. <i>British Journal of Haematology</i> , 2016 , 174, 480-3	4.5	12
364	Mechanisms and Treatment of Graft Failure 2016 , 944-958		6
363	Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2136-2140	4.7	94
362	Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1326-9	4.7	18
361	Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation. <i>Supportive Care in Cancer</i> , 2015 , 23, 3141-7	3.9	12
360	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. <i>Clinical Cancer Research</i> , 2015 , 21, 2993-3002	12.9	42
359	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015 , 100, 357-62	6.6	49
358	Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. <i>Molecular Therapy</i> , 2015 , 23, 757-68	11.7	116
357	Smart CARs engineered for cancer immunotherapy. <i>Current Opinion in Oncology</i> , 2015 , 27, 466-74	4.2	46
356	T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2015 , 22, 484-8	3.3	38

355	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015 , 21, 3771-82	12.9	117
354	CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1376-84	6.1	115
353	Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells. <i>Blood</i> , 2015 , 126, 51-51	2.2	2
352	Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2015 , 126, 518-518	2.2	4
351	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. <i>Blood</i> , 2015 , 126, 519-519	2.2	5
350	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 522-522	2.2	3
349	Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2015 , 126, 739-739	2.2	3
348	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , 2015 , 126, 796-796	2.2	8
347	Treatment with Anti-CD19 BiTE \square Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 861-861	2.2	4
346	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation For Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 930-930	2.2	2
345	Feasibility of administering a geriatric assessment to older adults with cancer using web-based and touchscreen platforms.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9536-9536	2.2	
344	Differences between patient and caregiver assessments and their association with caregiver burden in caregivers of older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9545-9545	2.2	
343	Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8581-8581	2.2	2
342	Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies. <i>Blood</i> , 2015 , 126, 2731-2731	2.2	
341	Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 1961-1961	2.2	2
340	Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. <i>Blood</i> , 2015 , 126, 3086-3086	2.2	
339	Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?. <i>Blood</i> , 2015 , 126, 3179-3179	2.2	
338	Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation. <i>Blood</i> , 2015 , 126, 1875-1875	2.2	

337	A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia. <i>Blood</i> , 2015 , 126, 735-735	2.2	1
336	Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 2072-5	4.7	14
335	Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3037-48	6.1	55
334	Iron chelators induce autophagic cell death in multiple myeloma cells. <i>Leukemia Research</i> , 2014 , 38, 988-96	2.6	35
333	Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1864-8	4.7	49
332	TLR9 is critical for glioma stem cell maintenance and targeting. <i>Cancer Research</i> , 2014 , 74, 5218-28	10.1	48
331	Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 920-8	4.7	9
330	Prevention and Treatment of Relapse Following Hematopoietic Cell Transplantation 2014 , 426-431		
329	Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 75-81	4	20
328	CS-1 Re-Directed Central Memory T Cell Therapy for Multiple Myeloma. <i>Blood</i> , 2014 , 124, 1114-1114	2.2	1
327	Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333. <i>Blood</i> , 2014 , 124, 2399-2399	2.2	2
326	Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies. <i>Blood</i> , 2014 , 124, 4483-4483	2.2	1
325	Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients. <i>Blood</i> , 2014 , 124, 183-183	2.2	
324	Acute myeloid leukemia therapeutics: CARs in the driver's seat. <i>OncImmunology</i> , 2013 , 2, e27214	7.2	7
323	T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. <i>Blood</i> , 2013 , 122, 3138-48	2.2	260
322	The myth of the second remission of acute leukemia in the adult. <i>Blood</i> , 2013 , 121, 1077-82	2.2	163
321	Selection For Brentuximab Vedotin Resistant Lymphoma Cell Lines Leads To Downregulation Of Surface CD30 Expression. <i>Blood</i> , 2013 , 122, 1280-1280	2.2	1
320	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2013 , 122, 2682-2682	2.2	6

319	Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT. <i>Blood</i> , 2013 , 122, 3374-3374	2.2	3
318	In Vivo Targeting Of Acute Myeloid Leukemia Using CpG-Stat3 siRNA Results In T Cell-Dependent Tumor Eradication. <i>Blood</i> , 2013 , 122, 4212-4212	2.2	0
317	Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2013 , 122, 4398-4398	2.2	1
316	Glioma IL13R α is associated with mesenchymal signature gene expression and poor patient prognosis. <i>PLoS ONE</i> , 2013 , 8, e77769	3.7	93
315	Quantitative Monitoring Of WilmsTumor 1 Expression In Predicting Relapse After Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2013 , 122, 2075-2075	2.2	
314	Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma. <i>Blood</i> , 2013 , 122, 1808-1808	2.2	
313	Increased Risk Of Brain Tumors Among First-Degree Relatives Of Patients With Therapy-Related Myelodysplasia and Acute Myeloid Leukemia (t-MDS/AML). <i>Blood</i> , 2013 , 122, 5228-5228	2.2	
312	Selective Anti Leukemic Activity Of Low Dose Decitabine In Combination With Ruxolitinib Against Stem/Progenitor Cells From Elderly AML Patients. <i>Blood</i> , 2013 , 122, 2690-2690	2.2	
311	Development Of t-MDS In Patients Undergoing Autologous Transplantation For Lymphoma Is Not Associated With Increased Frequency Of Mitochondrial DNA Mutations. <i>Blood</i> , 2013 , 122, 1535-1535	2.2	
310	Long-Term Health-Related Outcomes In Survivors Of Childhood Hematopoietic Cell Transplantation (HCT): A Report From The Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2013 , 122, 553-553	2.2	
309	S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. <i>Cancer Cell</i> , 2012 , 21, 642-654	24.3	191
308	Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. <i>Current Opinion in Oncology</i> , 2012 , 24, 182-90	4.2	18
307	Matched Cohort Analysis of Allogeneic Hematopoietic Cell Transplantation (HCT) with Total Marrow Irradiation/Fludarabine/Melphalan (TFM) Versus Fludarabine/Melphalan (FM) Conditioning for Acute Leukemia. <i>Blood</i> , 2012 , 120, 222-222	2.2	2
306	Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.. <i>Blood</i> , 2012 , 120, 3151-3151	2.2	1
305	Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL. <i>Blood</i> , 2012 , 120, 3699-3699	2.2	4
304	Genetic Susceptibility to Anthracycline-Related Congestive Heart Failure (CHF) in Survivors of Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2012 , 120, 589-589	2.2	1
303	Human Papillomavirus (HPV)-Attributable Subsequent Neoplasms (SNs) After Hematopoietic Cell Transplantation (HCT) Is a Potentially Preventable Outcome. <i>Blood</i> , 2012 , 120, 605-605	2.2	
302	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012 , 120, 3698-3698	2.2	

301	Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades. <i>Blood</i> , 2012 , 120, 606-606	2.2	2.2
300	Dasatinib Enhances Targeting of Human AML Leukemia Stem Cells by Chemotherapeutic Agents Via Activation of p53. <i>Blood</i> , 2012 , 120, 3590-3590	2.2	
299	Nrf2 Deficiency Leads to Reduced Hematopoietic Stem Cell Self-Renewal and Increased Sensitivity to Genotoxic Stressors Through Impaired P53 Function. <i>Blood</i> , 2012 , 120, 397-397	2.2	
298	Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia. <i>Blood</i> , 2012 , 120, 218-218	2.2	
297	Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. <i>Blood</i> , 2011 , 117, 1888-98	2.2	135
296	Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. <i>Blood</i> , 2011 , 117, 309-15	2.2	58
295	Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). <i>Blood</i> , 2011 , 118, 1413-20	2.2	140
294	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. <i>Blood</i> , 2011 , 118, 1255-63	2.2	382
293	Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1463-73	1.9	30
292	Primary anaplastic large-cell lymphoma associated with breast implants. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1481-7	1.9	47
291	Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2011 , 118, 664-664	2.2	5
290	Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/AML) After Conventionally-Treated Breast Cancer: Impact of Cytogenetics on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011 , 118, 4149-4149	2.2	
289	Genetic Susceptibility to Therapy-Related Leukemia [Role of Expression Quantitative Trait Loci (eQTL)]. <i>Blood</i> , 2011 , 118, 2438-2438	2.2	
288	Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study. <i>Blood</i> , 2011 , 118, 2555-2555	2.2	
287	Nrf2 Deficiency Leads to Altered Hematopoietic Stem Cell Function and Increased Sensitivity to Alkylating Agent Induced Myeloid Dysplasia. <i>Blood</i> , 2011 , 118, 3828-3828	2.2	
286	Tissue Parenchymal Cell Expression of B7-H1 Inhibits Infiltrating T Cell Expansion and Prevents Persistence of Graft-Versus-Host Disease. <i>Blood</i> , 2011 , 118, 2974-2974	2.2	
285	Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients. <i>Blood</i> , 2011 , 118, 5108-5108	2.2	
284	Eosinophilia As a Biomarker Predicting the Occurrence of Chronic Graft Versus Host Disease. <i>Blood</i> , 2011 , 118, 4084-4084	2.2	

283	Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2011 , 118, 953-953	2.2	
282	Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. <i>Journal of Immunology</i> , 2010 , 184, 4284-94	5.3	26
281	Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. <i>Blood</i> , 2010 , 116, 3129-39; quiz 3377	2.2	175
280	Response: A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 different conditioning regimens. <i>Blood</i> , 2010 , 115, 4317-4317	2.2	78
279	Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period. <i>Blood</i> , 2010 , 116, 933-933	2.2	
278	Dose Dependent Effect of Deferasirox on Hematopoietic Progenitors of Myelodysplastic Syndrome. <i>Blood</i> , 2010 , 116, 3994-3994	2.2	
277	Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era. <i>Blood</i> , 2010 , 116, 902-902	2.2	
276	Extramedullary Relapse Following Reduced Intensity AlloHCT for Adult AML.. <i>Blood</i> , 2010 , 116, 3467-3467		
275	What is the role of reduced-intensity transplantation in the treatment of older patients with AML?. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 406-13	3.1	10
274	Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when?. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 557-66	4.2	3
273	Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1407-14	4.7	64
272	Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. <i>Hematology/Oncology Clinics of North America</i> , 2009 , 23, 1011-31, vi	3.1	3
271	A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR.. <i>Blood</i> , 2009 , 114, 2194-2194	2.2	4
270	Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.. <i>Blood</i> , 2009 , 114, 2771-2771	2.2	1
269	Neurocognitive Function and Its Impact On Return to Work in Patients Treated with Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2009 , 114, 521-521	2.2	4
268	Graft Versus Host Disease Correlates with Increased Survival After Allogeneic Stem Cell Transplant for Mature T-Cell Lymphomas: Evidence of Graft Versus T-Cell Lymphoma Effect.. <i>Blood</i> , 2009 , 114, 3367-3367	2.2	
267	A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).. <i>Blood</i> , 2009 , 114, 1225-1225	2.2	
266	Late Hospitalizations in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): Report From the Bone Marrow Transplant Study (BMTSS).. <i>Blood</i> , 2009 , 114, 807-807	2.2	

265	Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 3423-3423	2.2	
264	Purity, Potency and Safety: Quality Management Reports (QMR) as the Basis for An Effective Continuous Process Improvement System in An Academic Gene Therapy Program.. <i>Blood</i> , 2009 , 114, 1417-1417	2.2	
263	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).. <i>Blood</i> , 2009 , 114, 1192-1192	2.2	
262	Mechanisms of Susceptibility to 11q23 MLL Gene Locus Rearrangements in CD34+ Cells Exposed to Etoposide.. <i>Blood</i> , 2009 , 114, 185-185	2.2	
261	A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 3403-3403	2.2	
260	Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009 , 114, 1682-1682	2.2	
259	Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009 , 114, 2323-2323	2.2	1
258	Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.. <i>Blood</i> , 2009 , 114, 1690-1690	2.2	
257	Genetic Susceptibility to Therapy-Related Leukemia (t-MDS/AML) After Hodgkin Lymphoma (HL) or Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009 , 114, 199-199	2.2	
256	90.y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).. <i>Blood</i> , 2009 , 114, 3357-3357	2.2	
255	Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. <i>Journal of Immunology</i> , 2008 , 180, 7028-38	5.3	160
254	Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. <i>Blood</i> , 2008 , 112, 903-9	2.2	85
253	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. A California Cancer Consortium Study.. <i>Blood</i> , 2008 , 112, 1564-1564	2.2	5
252	Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years. <i>Blood</i> , 2008 , 112, 194-194	2.2	3
251	HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for B Cell Non Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2008 , 112, 2181-2181	2.2	2
250	First in Human Engraftment of Anti-HIV Lentiviral Vector Gene Modified CD34+ Peripheral Blood Progenitor Cells in the Treatment of AIDS Related Lymphoma (ARL).. <i>Blood</i> , 2008 , 112, 2348-2348	2.2	3
249	Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).. <i>Blood</i> , 2008 , 112, 3326-3326	2.2	1
248	Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor. <i>Blood</i> , 2008 , 112, 797-797	2.2	1

247	Analysis of 120 Pediatric Patients with Non-Malignant Disorders Transplanted Using Unrelated Plasma Depleted Cord Blood and the Role of Post-Thaw Wash. <i>Blood</i> , 2008 , 112, 4406-4406	2.2	
246	Decline in Sexual Functioning Over a 3-Year Period after Hematopoietic Cell Transplantation (HCT): Gender-Specific Impact of Total Body Irradiation (TBI) and Chronic Graft-Versus-Host Disease (cGvHD). <i>Blood</i> , 2008 , 112, 743-743	2.2	
245	Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs. <i>Blood</i> , 2008 , 112, 3628-3628	2.2	
244	Longitudinal Trends in Peripheral Blood Parameters Predict Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/ AML) after Autologous Transplantation for Lymphoma.. <i>Blood</i> , 2008 , 112, 2133-2133	2.2	
243	Truncation in CCND1 mRNA 3' UTR Is Associated with An Aggressive Phenotype and Chemoresistance. <i>Blood</i> , 2008 , 112, 5287-5287	2.2	
242	Differential Morbidity by Ethnicity in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2008 , 112, 454-454	2.2	
241	Impact of Donor Serostatus on CMV Reactivation and Reconstitution of Multi-Function CMV-Specific T Cells in CMV-Positive Transplant Recipients. <i>Blood</i> , 2008 , 112, 4339-4339	2.2	
240	Ethnic Differences in the Prevalence of, and Predictors for Anxiety, Depression, and Somatic Distress in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2008 , 112, 741-741	2.2	
239	Delayed Cytomegalovirus (cmv) Infection Following Hematopoietic Cell Transplantation (HCT): City of Hope (COH) Experience.. <i>Blood</i> , 2008 , 112, 1155-1155	2.2	0
238	Genomic Alterations in Hodgkin \bar{B} and Reed/Sternberg (HRS) Cells at Disease Onset Reveals Distinct Signatures for Chemosensitive and Primary Refractory Hodgkin \bar{B} Lymphoma.. <i>Blood</i> , 2008 , 112, 1451-1451 ^{2,2}		
237	Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity. <i>Journal of Immunotherapy</i> , 2007 , 30, 644-54	5	36
236	Pre-Clinical Development of a Subunit Vaccine Expressing an IE1-IE2 Fusion Protein of HCMV.. <i>Blood</i> , 2007 , 110, 165-165	2.2	3
235	Updated Results of High-Dose Yttrium 90 (90Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AH SCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin \bar{B} Lymphoma.. <i>Blood</i> , 2007 , 110, 1891-1891	2.2	7
234	Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.. <i>Blood</i> , 2007 , 110, 4989-4989	2.2	1
233	Burdern of Long-Term Morbidity after Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study (BMTSS).. <i>Blood</i> , 2007 , 110, 832-832	2.2	2
232	High dose chemotherapy for breast cancer: Out with the old, in with the new?. <i>Women's Oncology Review</i> , 2007 , 6, 105-107		
231	Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.. <i>Blood</i> , 2007 , 110, 3021-3021	2.2	
230	Non-Myeloablative Conditioning Regimen (NMCR) for Allogeneic Bone Marrow Transplantation (BMT) in Patients with Severe Aplastic Anemia (SAA).. <i>Blood</i> , 2007 , 110, 4943-4943	2.2	

229	Multicytokine and Polyfunctional CMV-Specific T Cells Are Associated with Stem Cell Transplant Donor CMV Serostatus.. <i>Blood</i> , 2007 , 110, 4992-4992	2.2	
228	Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 1089-1089	2.2	
227	Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in High Risk B-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007 , 110, 3500-3500	2.2	
226	Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 3030-3030	2.2	
225	Chronic Graft vs. Host Disease (cGVHD) Hinders Long-Term Functional Recovery after Hematopoietic Cell Transplantation.. <i>Blood</i> , 2007 , 110, 634-634	2.2	
224	In Vivo Activated CD103+CD4+ Regulatory T Cells Ameliorate Ongoing Chronic GVHD.. <i>Blood</i> , 2007 , 110, 350-350	2.2	
223	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. <i>Cancer Research</i> , 2006 , 66, 10995-1004 ¹	10.1	369
222	Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 306-15	4.7	143
221	A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 438-53	4.7	151
220	Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 511-7	4.7	82
219	Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1326-34	4.7	88
218	A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.. <i>Blood</i> , 2006 , 108, 3043-3043	2.2	6
217	Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy with Interleukin-2 Versus Observation for Patients with Non-Hodgkin's Lymphoma: Results of a Phase III Randomized Trial by the Southwest Oncology Group (SWOG 9438).. <i>Blood</i> , 2006 , 108, 326-326	2.2	1
216	Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression.. <i>Blood</i> , 2006 , 108, 2165-2165	2.2	
215	The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 2866-2866	2.2	0
214	Donor CD8+ T Cells Mediate GVL without GVHD in Recipients Conditioned with Anti-CD3 mAb.. <i>Blood</i> , 2006 , 108, 192-192	2.2	
213	A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.. <i>Blood</i> , 2006 , 108, 1948-1948	2.2	1
212	Functional Comparison and Longitudinal Assessment of Tri-Functional T-Cells Recognizing CMV pp65 and IE-1 Polypeptides in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.. <i>Blood</i> , 2006 , 108, 2936-2936	2.2	

211	Innovations in autologous transplantation for hematologic malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 28-33	4.7	2
210	Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. <i>Blood</i> , 2005 , 105, 1622-31	2.2	95
209	Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6163-71	2.2	107
208	Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor?. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 18-9		
207	Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.. <i>Blood</i> , 2005 , 106, 1130-1130	2.2	11
206	Predictors of Avascular Necrosis (AVN) of Bone after Long-Term Follow-Up of Allogeneic and Autologous Hematopoietic Cell Transplantation (HCT) for Malignant and Non-Malignant Disorders.. <i>Blood</i> , 2005 , 106, 700-700	2.2	
205	Peptide Libraries to CMV Antigens Predict Levels of Cytotoxic Function of CMV-Specific CTL Populations in PBMC from HSCT Recipients.. <i>Blood</i> , 2005 , 106, 478-478	2.2	
204	Large Granular Lymphocytosis Following Transplantation: Institutional Experience over a 10-Year Period at City of Hope.. <i>Blood</i> , 2005 , 106, 2024-2024	2.2	
203	Pre-Stimulation of CML CD34+ Cells with High Concentrations of Growth Factors Counters Imatinib-Mediated Proliferation Suppression and Enhances Apoptosis of Non-Dividing Cells.. <i>Blood</i> , 2005 , 106, 2479-2479	2.2	
202	Effects of Elevated BCR/ABL Expression Level on Cellular Transformation and Sensitivity to Imatinib in Primitive Human Hematopoietic Cells.. <i>Blood</i> , 2005 , 106, 1998-1998	2.2	
201	Impact of Chronic Graft Versus Host Disease (cGVHD) on the Health Status of Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2005 , 106, 702-702	2.2	
200	The MDS-Associated Gene DLK Modulates Gene Expression in Human Myeloid Cells by Altering the Activity of Multiple Transcription Factors.. <i>Blood</i> , 2005 , 106, 3428-3428	2.2	
199	Health-Risk Behaviors among Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2005 , 106, 748-748	2.2	
198	Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. <i>Blood</i> , 2004 , 104, 1898-906	2.2	127
197	Expression of DLK/PREF1 Results in Inhibition of Human Myeloid Cell Differentiation and Proliferation through Distinct Molecular Mechanisms.. <i>Blood</i> , 2004 , 104, 202-202	2.2	6
196	Primary Anaplastic Large Cell Lymphoma of the Breast Occurring in Patients with Silicone Breast Implants.. <i>Blood</i> , 2004 , 104, 4563-4563	2.2	1
195	Pregnancy Outcomes after Hematopoietic Cell Transplantation (HCT): A Report from the BMT Survivor Study.. <i>Blood</i> , 2004 , 104, 58-58	2.2	1
194	Functional Limitations, Physical Disability and Social Competence among HCT Survivors Transplanted during Childhood or Adolescence: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004 , 104, 59-59	2.2	1

193	Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.. <i>Blood</i> , 2004 , 104, 894-894	2.2	4
192	Health Care Utilization by Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004 , 104, 2196-2196	2.2	
191	Donor CD8+ T Cells Facilitate Induction of Chimerism and Tolerance without GVHD in Autoimmune NOD Mice Conditioned with Anti-CD3 mAb.. <i>Blood</i> , 2004 , 104, 1204-1204	2.2	1
190	A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant.. <i>Blood</i> , 2004 , 104, 2752-2752	2.2	3
189	Matched Unrelated Donor Hematopoietic Cell Transplantation Following Reduced-Intensity Conditioning for Treatment of Myelofibrosis.. <i>Blood</i> , 2004 , 104, 2769-2769	2.2	1
188	Cytomegalovirus Infections Following Reduced-Intensity Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 2245-2245	2.2	
187	Effect of Growth Factor Stimulation on Imatinib-Mediated Proliferation Inhibition and Apoptosis of CML CD34+ Cells.. <i>Blood</i> , 2004 , 104, 2967-2967	2.2	3
186	Depression, Somatic Distress and Anxiety in Adult Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004 , 104, 231-231	2.2	
185	Feasibility and Efficacy of Mobilization of BCR/ABL- PBSC in CML Patients Receiving Imatinib.. <i>Blood</i> , 2004 , 104, 2858-2858	2.2	1
184	Prognostic Relevance of Early-Onset Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.. <i>Blood</i> , 2004 , 104, 423-423	2.2	
183	Health-Related Quality of Life (HRQL) in Adult Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004 , 104, 2254-2254	2.2	1
182	T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. <i>Blood</i> , 2003 , 101, 1637-44	2.2	213
181	Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. <i>Journal of Clinical Oncology</i> , 2003 , 21, 615-23	2.2	27
180	Abnormal growth factor modulation of beta1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors. <i>British Journal of Haematology</i> , 2001 , 115, 845-53	4.5	12
179	High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2000 , 89, 680-689	6.4	54
178	Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2000 , 28, 318-28	5	47
177	Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. <i>Blood</i> , 2000 , 95, 1588-1593	2.2	245
176	Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. <i>Blood</i> , 2000 , 96, 4075-4083	2.2	1304

175	Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000 , 1, 46-54		46
174	Autologous bone marrow transplantation for non-Hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease. <i>British Journal of Haematology</i> , 1998 , 103, 651-2	4.5	72
173	Cellular immunotherapy and autologous transplantation for hematologic malignancy. <i>Immunological Reviews</i> , 1997 , 157, 231-40	11.3	42
172	Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia 1996 , 78, 1899-1905		33
171	Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia 1996 , 78, 1899		2
170	Trisomy 11: an association with stem/progenitor cell immunophenotype. <i>British Journal of Haematology</i> , 1995 , 90, 266-73	4.5	30
169	Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. <i>Journal of Medical Virology</i> , 1994 , 43, 103-10	19.7	292
168	High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994 , 73, 125-34	6.4	25
167	Acalculous cholecystitis in bone marrow transplant patients. <i>Cancer</i> , 1993 , 71, 354-8	6.4	19
166	Pharmacokinetics of high-dose etoposide. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 561-4	6.1	22
165	Microcytosis in Hodgkin disease associated with unbalanced globin chain synthesis. <i>American Journal of Hematology</i> , 1986 , 23, 123-9	7.1	4
164	Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients. <i>Journal of Infectious Diseases</i> , 1986 , 153, 780-7	7	52
163	Bone marrow transplantation for hematologic malignancies. <i>Journal of Cellular Physiology</i> , 1982 , 1, 99-102		5
162	Noncutaneous peripheral T-cell lymphoma histologically resembling mycosis fungoides. <i>Cancer</i> , 1982 , 49, 1839-47	6.4	31
161	Hemolytic anemia in Wilson disease: clinical findings and biochemical mechanisms. <i>American Journal of Hematology</i> , 1980 , 9, 269-75	7.1	43
160	Radiotherapeutic Principles of Hematopoietic Cell Transplantation333-350		
159	Cord Blood Hematopoietic Cell Transplantation559-576		11
158	Immune Reconstitution Following Hematopoietic Cell Transplantation222-231		1

157	The Pathophysiology of Graft-Versus-Host Disease208-221	2
156	A History of Allogeneic Hematopoietic Cell Transplantation1-7	4
155	Uses and Growth of Hematopoietic Cell Transplantation15-21	12
154	The History of Autologous Hematopoietic Cell Transplantation8-14	4
153	Expansion of Hematopoietic Stem Cells88-101	
152	Molecular Biology of Stem Cell Renewal64-71	
151	Biology of Hematopoietic Stem and Progenitor Cells36-63	1
150	Mechanisms of Tolerance188-207	
149	Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation102-115	
148	Cellular Biology of Hematopoiesis72-87	
147	Hematopoietic Cell Transplantation for Multiple Myeloma845-859	
146	Autologous Graft-vs.-Host Disease405-413	
145	Biology of Hematopoietic Stem and Progenitor Cells69-95	1
144	Graft-vs.-Host Disease633-664	3
143	Nonmyeloablative Therapy and Hematopoietic Cell Transplantation for Hematologic Disorders1164-1176	2
142	Outcomes Research in Hematopoietic Cell Transplantation428-441	1
141	In Utero Transplantation577-589	1
140	Histocompatibility145-162	1

139	Nursing Role in Hematopoietic Cell Transplantation461-477	1
138	Autologous Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma1207-1220	1
137	Hematopoietic Cell Transplantation for Storage Diseases1455-1470	2
136	Chlorotoxin Redirects Chimeric Antigen Receptor T Cells for Specific and Effective Targeting of Glioblastoma	2
135	Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors	1
134	Hematopoietic Cell Transplantation for Immunodeficiency Diseases1430-1442	3
133	Hematopoietic Cell Transplantation for Fanconi Anemia1483-1504	5
132	Clinical Trials of Gene Marking and Gene Therapy Using Hematopoietic Stem Cells118-129	1
131	Preparative Regimens and Modification of Regimen-Related Toxicities158-177	1
130	T-Cell Depletion to Prevent Graft-vs.-Host Disease221-233	3
129	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation234-244	1
128	Antibody Mediated Purging244-253	1
127	Uses and Growth of Hematopoietic Cell Transplantation9-15	9
126	Mechanisms of Tolerance300-323	2
125	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases324-343	1
124	Murine Models for Graft-Vs.-Host Disease344-352	1
123	The Pathophysiology of Graft-Vs.-Host Disease353-368	7
122	Overview of Hematopoietic Cell Transplantation Immunology16-30	1

121	Hematopoietic Cell Donors538-549	1
120	Cord Blood Hematopoietic Cell Transplantation550-564	3
119	Fungal Infections After Hematopoietic Cell Transplantation683-700	1
118	Cytomegalovirus Infection701-726	4
117	Herpes Simplex Virus Infections727-731	1
116	Epstein-Barr Virus Infection749-756	1
115	Gastrointestinal and Hepatic Complications769-810	3
114	Immunological Reconstitution Following Hematopoietic Cell Transplantation853-861	4
113	Growth and Development After Hematopoietic Cell Transplantation929-943	4
112	Delayed Complications After Hematopoietic Cell Transplantation944-961	2
111	Secondary Malignancies After Hematopoietic Cell Transplantation962-977	2
110	Allogeneic Transplantation for Myelodysplastic and Myeloproliferative Disorders1084-1095	1
109	Hematopoietic Cell Transplantation from Unrelated Donors1132-1149	1
108	Autologous Hematopoietic Cell Transplantation for Multiple Myeloma1262-1282	1
107	Hematopoietic Cell Transplantation for Neuroblastoma1333-1344	1
106	Nutrition Support of the Hematopoietic Cell Transplant Recipient1551-1569	2
105	Oral Complications of Hematopoietic Cell Transplantation1589-1607	7
104	Growth and Development after Hematopoietic Cell Transplantation1608-1619	6

103	Delayed Nonmalignant Complications after Hematopoietic Cell Transplantation1620-1637	3
102	Neurologic Complications of Hematopoietic Cell Transplantation1653-1663	2
101	Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients1664-1670	2
100	Murine Models of Graft-versus-Host Disease and Graft-versus-Tumor Effect176-187	3
99	The Human Graft-versus-Tumor Response and How to Exploit It232-247	1
98	Dendritic Cells in Hematopoietic Cell Transplantation248-263	1
97	Pharmacologic Basis for High-dose Chemotherapy287-315	4
96	High-dose Preparatory Regimens316-332	2
95	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation365-377	1
94	Pathology of Hematopoietic Cell Transplantation390-405	1
93	The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation443-460	2
92	Psychosocial Issues in Hematopoietic Cell Transplantation488-501	2
91	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients502-514	1
90	Bone Marrow and Peripheral Blood Cell Donors and Donor Registries544-558	4
89	Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy590-604	3
88	Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors657-674	1
87	Hematopoietic Cell Transplantation from Unrelated Donors675-691	2
86	Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia761-774	3

85	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults791-805	1
84	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children806-826	1
83	Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders827-844	1
82	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia897-913	1
81	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies1043-1051	1
80	Hematopoietic Cell Transplantation for Immunodeficiency Diseases1105-1124	1
79	Hematopoietic Cell Transplantation for Storage Diseases1136-1162	3
78	Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation1226-1243	2
77	Vascular Access and Complications1244-1256	1
76	Pharmacologic Prevention of Acute Graft-Versus-Host Disease1257-1274	5
75	Manifestations and Treatment of Acute Graft-Versus-Host Disease1287-1303	10
74	Chronic Graft-versus-Host Disease: Clinical Manifestations and Therapy1304-1324	8
73	Fungal Infections after Hematopoietic Cell Transplantation1346-1366	5
72	Cytomegalovirus Infection1367-1381	5
71	Herpes Simplex Virus Infections1382-1387	6
70	Varicella-zoster Virus Infections1388-1409	5
69	Gastrointestinal and Hepatic Complications1434-1455	4
68	Lung Injury Following Hematopoietic Cell Transplantation1456-1472	12

- 67 Kidney and Bladder Complications of Hematopoietic Cell Transplantation 1473-1486 2
- 66 Methods for Gene Transfer: Genetic Manipulation of Hematopoietic Stem Cells 107-117
- 65 AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy 1369-1384
- 64 Marrow Transplantation in Thalassemia 1407-1416
- 63 Pharmacologic Basis for High-Dose Chemotherapy 130-157
- 62 Radiotherapeutic Principles of Hematopoietic Cell Transplantation 178-197
- 61 Radioimmunotherapy and Hematopoietic Cell Transplantation 198-208
- 60 Molecular Inhibition of Gene Expression in Hematopoietic Cells 258-271
- 59 The Detection and Significance of Minimal Residual Disease 272-285
- 58 Pathology of Hematopoietic Cell Transplantation 286-299
- 57 Adoptive Immunotherapy With Antigen-Specific T Cells 380-404
- 56 The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation 447-462
- 55 Clinical and Administrative Support for Hematopoietic Cell Transplant Programs 463-468
- 54 Nursing Issues in Hematopoietic Cell Transplantation 469-482
- 53 Psychosocial Issues in Hematopoietic Cell Transplantation 497-506
- 52 Histocompatibility 31-42
- 51 Hematopoietic Cell Procurement, Processing and Transplantation: Regulation and Accreditation 529-537
- 50 In Utero Transplantation 565-575

- 49 Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Support of High-Dose Cancer Therapy 576-587
- 48 Recombinant Growth Factors After Hematopoietic Cell Transplantation 613-623
- 47 The Hematopoietic Microenvironment 53-61
- 46 Nutritional Support of Hematopoietic Cell Recipients 883-893
- 45 Oral Complications 911-928 1
- 44 Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia 979-1001
- 43 Allogeneic Hematopoietic Cell Transplantation for Adult Patients With Acute Myeloid Leukemia 1025-1039
- 42 Allogeneic Transplantation for Acute Myeloid Leukemia in Children 1040-1054
- 41 Allogeneic Transplantation for Acute Lymphoblastic Leukemia in Children 1067-1083
- 40 Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma 1096-1104
- 39 Allogeneic Transplantation for Lymphoma and Chronic Lymphocytic Leukemia 1105-1115
- 38 Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors 1116-1131
- 37 Allogeneic Hematopoietic Cell Transplantation for Solid Tumors 1177-1187
- 36 Autologous and Allogeneic Hematopoietic Cell Transplantation for Hodgkin's Disease 1189-1206
- 35 Expansion of Hematopoietic Stem Cells 96-106
- 34 Autologous Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia 1250-1261
- 33 Autologous Hematopoietic Cell Transplantation for AL Amyloidosis 1283-1297
- 32 Hematopoietic Cell Transplantation in Germ Cell Tumors 1308-1319

- 31 Hematopoietic Cell Transplantation for Brain Tumors1345-1353
- 30 Hematopoietic Cell Transplantation for Pediatric Patients With Solid Tumors1354-1368
- 29 Genetic Manipulation of Hematopoietic Stem Cells116-128
- 28 Critical Care of the Hematopoietic Cell Transplant Recipient1539-1550
- 27 Secondary Malignancies after Hematopoietic Cell Transplantation1638-1652
- 26 Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation163-175
- 25 Radioimmunotherapy and Hematopoietic Cell Transplantation351-364
- 24 The Detection and Significance of Minimal Residual Disease376-389
- 23 Biostatistical Methods in Hematopoietic Cell Transplantation406-427
- 22 Hematopoietic Cell Procurement, Processing, and Transplantation: Standards, Accreditation, and Regulation533-543
- 21 Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Embryonic Stem Cells23-35
- 20 Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation645-656
- 19 Hematopoietic Cell Transplantation for Aplastic Anemia705-726
- 18 Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia751-760
- 17 Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia775-790
- 16 Hematopoietic Cell Transplantation for Hodgkin's Disease860-877
- 15 Non-Hodgkin's Lymphoma878-896
- 14 Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis914-930

- 13 Hematopoietic Cell Transplantation for Breast Cancer931-947
- 12 Hematopoietic Cell Transplantation in Germ Cell Tumors948-957
- 11 Hematopoietic Cell Transplantation for Renal Cell and other Solid Tumors958-959
- 10 Hematopoietic Cell Transplantation for Neuroblastoma970-984
- 9 Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors985-1000
- 8 Hematopoietic Cell Transplantation for Patients with Human Immunodeficiency Virus Infection1001-1013
- 7 Hematopoietic Cell Transplantation for Rare Hematologic Malignancies1030-1042
- 6 Management of Relapse after Hematopoietic Cell Transplantation1059-1075
- 5 Hematopoietic Cell Transplantation for Thalassemia1077-1089
- 4 Hematopoietic Cell Transplantation for Fanconi's Anemia1178-1199
- 3 Mechanisms and Treatment of Graft Failure1201-1218
- 2 EpsteinBarr Virus Infection1410-1418
- 1 Common Potential Drug Interactions Following Hematopoietic Cell Transplantation1523-1538